


Clinical and Pathology Setting for Neuroendocrine Prostate Cancer


Localized Hormone Naïve Prostate Cancer

NE cells commonly observed Some reports suggest more are bad prognostic finding Clinical implications uncertain and no impact on care



Advanced met PCA or CRPC

Observed in 10%+ cases Diagnosis associated with 7 month med survival Limited treatment –including PARPi and Platinum





Epstein et al, AJSP 2014

Pathologist's Role in PCA Diagnosis 2018

	Localized Prostate Cancer	CRPC
Evidence-Based Support	Established standard	Anecdotal
Formal Training	Established and Rigorous	Rare, Informal and based on institutional practices
Major Clinical Role	Diagnosis with Gleason Grade (Bx, RP), Stage (RP), Margin status (RP)	Prostate Cancer versus Other (melanoma, lung, etc.)
Molecular Testing	p63, 34beta E12, AMACR, ERG, CK	CK, PSA, ERG, AR, (others based on Hx)
Experienced Pathologists	100%	1-5%

Gleason's role in developing a robust system





-Minnesota Multiphasic Personality Inventory (MMPI) *a standardized psychometric test* (1943)

-Evidenced-based research leads to enduring grading system (1960s)

-Through education and formal training it has become highly reproducible

M.A. Rubin ISUP Meeting copyright 2019

Towards Classification of CRPC in Motion

	2010					
Bx or RI	P from men on ADT	Precision medicine approaches (e.g., UM, SU2C-PCF Stud				
Autopsies (Hopkins/Mich/UW)						
	Histology		WES, WGS	cfDNA, CTC		
	IHC		RNAseq	Mol.Imaging (e.g., PSMA)		
	Transcriptomics		Epigenetic			
	Array CGH		Proteomic			
	FISH					
M.A. Rubin ISUP Meeting copyright 2019						

Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation

Jonathan I. Epstein, MD,*†‡ Mahul B. Amin, MD,§ Himisha Beltran, MD, || Tamara L. Lotan, MD,*‡ Juan-Miguel Mosquera, MD, MSc,¶# Victor E. Reuter, MD,** Brian D. Robinson, MD,¶# Patricia Troncoso, MD,†† and Mark A. Rubin, MD¶#

Based on work from a July 31, 2013, the Prostate Cancer Foundation assembled a working committee on the molecular biology and pathologic classification of neuroendocrine (NE) differentiation in prostate cancer.

M.A. Rubin ISUP Meeting copyright 2019


AJSP 2014


TABLE 1. Pathologic Classification of NE Differentiation inProstate Carcinoma


Usual prostate adenocarcinoma with NE differentiation Adenocarcinoma with Paneth cell NE differentiation Carcinoid tumor Small cell carcinoma LCNEC Mixed (small or large cell) NE carcinoma—acinar adenocarcinoma


M.A. Rubin ISUP Meeting copyright 2019


AJSP 2014











MODERN PATHOLOGY (2018) 31, S122-S132

© 2018 USCAP, Inc All rights reserved 0893-3952/18 \$32.00

Neuroendocrine tumors of the prostate

Samson W Fine


Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA


Neuroendocrine (NE) differentiation in tumors of the prostate or in the setting of prostate cancer (PCa) is rare. A survey of these lesions is presented, including usual PCa with focal NE marker-positive cells, Paneth cell-like change, prostatic 'carcinoid', high-grade NE carcinoma, as well as other tumors that do not fit neatly into these categories. The most significant clinical and pathologic features, emerging molecular evidence and the importance of differentiating NE tumors involving the prostate from secondary involvement are highlighted. *Modern Pathology* (2018) **31**, S122–S132; doi:10.1038/modpathol.2017.164

Prostate Cancer Foundation working committee proposed classification	2016 World Health Organization genitourinary tumor classification
Usual prostate adenocarcinoma with NE differentiation Adenocarcinoma with Paneth cell NE differentiation Carcinoid tumor Small cell carcinoma LCNEC Mixed (small or large cell) NE carcinoma-acinar adenocarcinoma	NE cells in usual prostate cancer Adenocarcinoma with Paneth cell-like NE differentiation Well-differentiated NE tumor (carcinoid) Small cell NE carcinoma Large cell NE carcinoma

Abbreviations: LCNEC, large cell neuroendocrine carcinoma; NE, neuroendocrine.

Characteristics that help define NEPC





Genomic enrichment and depletion during AR targeted therapy

Characteristics that help define NEPC

	High	AR Signaling	Low	
	No	NE Markers	Yes	8
	wt/loss	TP53	Loss	
	wt/loss	RB1	Loss	
CRPC (adenoc	carcinoma)			Small cell/NEPC

Consensus Recommendation Proposal

1) Routine staining for NE expression of localized PCa in the absence of morphologic changes not recommended

2) The term "NE" differentiation best reserved for high-grade cancers (i.e., not carcinoids)

3) Advanced metPCA or CRPC may manifest a range of features that include NE differentiation

4) A combination of molecular evaluation and pathology features may be best approach to classification